Can we select NSCLC patients for immune checkpoint therapy?

18 / 38

Blood TMB and atezolizumab benefit
Cut off : bTMB ≥16 ?
Not correlation with PFS
Lim – Ann Oncol 2015 * Gandara – ESMO 2017
~30% NSCLC have inadequate tumor tissue for molecular testing at diagnosis
Interaction P = 0.75
Months Months
bTMB ≥16 bTMB <16
Atezolizumab (N = 216)
Docetaxel (N = 209)
+ Censored
Atezolizumab (N = 77)
Docetaxel (N = 81)
+ Censored
Overall Survival (%) Overall Survival (%)
OS in OAK trial
13.5 vs. 6.8 mo.
394 gene-based NGS assay